— Know what they know.
Not Investment Advice
Also trades as: DIA.MI (MIL) · $vol 19M

DSRLF OTC

DiaSorin S.p.A.
1W: -2.3% 1M: -2.3% 3M: +13.1% YTD: +10.5% 1Y: -10.9% 3Y: -5.3% 5Y: -56.0%
$84.00
-2.00 (-2.33%)
 
Weekly Expected Move ±1.2%
$82 $83 $84 $85 $86
OTC · Healthcare · Medical - Diagnostics & Research · Tech Score Neutral · Power 53 · $4.2B mcap · 21M float · 0.0006% daily turnover · Short 100% of daily vol
Smart Money Score
No convergence signal
Key Statistics
Market Cap$4.2B
52W Range66.5-94.25
Volume5
Avg Volume116
Beta0.68
Dividend$1.51
Analyst Ratings
1 Buy 2 Hold 1 Sell
Consensus Hold
Company Info
CEOCarlo Rosa
Employees3,272
SectorHealthcare
IndustryMedical - Diagnostics & Research
IPO Date2009-09-11
Via Crescentino snc
Saluggia, VC 13040
IT
39 01 614871
About DiaSorin S.p.A.

Established in 1968 and based in Saluggia, Italy, DiaSorin S.p.A. is a prominent player in the global diagnostics market. The company specializes in the creation, production, and distribution of sophisticated immunodiagnostic and molecular diagnostic testing kits. Its extensive reach spans across Europe, Africa, North, Central, and South America, the Asia Pacific region, and China. Among its offerings, DiaSorin provides a range of LIAISON platforms for immunodiagnostics, including the LIAISON XS, LIAISON XL, and LIAISON XL LAS systems. For molecular diagnostics, the LIAISON MDX platform is key, designed to amplify nucleic acids for identifying viruses in patient biological samples, thereby enabling the diagnosis of viral infections. DiaSorin also actively engages in strategic alliances to expand its diagnostic capabilities. These include a partnership with QIAGEN for a latent tuberculosis detection solution, a collaboration with TTP to develop molecular Point-of-Care solutions, and an agreement with MeMed to introduce a test that distinguishes between viral and bacterial infections.

Recent Insider Trades

No insider trades found

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms